Showing 3501-3510 of 6808 results for "".
- Lilly Resubmits BLA for Lebrikizumabhttps://practicaldermatology.com/news/lilly-resubmits-bla-lebrikizumab/2462907/Eli Lilly and Company announced as part of its 2024 first-quarter financial report that it as resubmitted the biologic license application (BLA) for lebrikizumab to the U.S. Food and Drug Administration for the treatment of people 12 and older with moderate-to-severe atopic dermatitis (eczema), t
- EPI Health Issues Voluntary Recall of Several Products Following Bankruptcyhttps://practicaldermatology.com/news/epi-health-issues-voluntary-recall-several-products-following-bankruptcy/2462869/EPI Health (Novan) is initiating a voluntary recall of various within-expiry human drug products as a result of the closures and discontinuation of the post-marketing quality, regulatory and pharmacovigilance activities for these marketed products. The moves comes after EPI filed Chapter 7 bankru
- UCB Receives European Approval for Hidradenitis Suppurativa Treatment Bimzelxhttps://practicaldermatology.com/news/ucb-receives-european-approval-hidradenitis-suppurativa-treatment-bimzelx/2462815/The European Commission has granted marketing authorization for UCB’s Bimzelx (bimekizumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy.1 Bimzelx is the first IL-17A and IL-17F bi
- FDA Issues Alert for Counterfeit Botox Across Multiple U.S. Stateshttps://practicaldermatology.com/news/fda-issues-alert-counterfeit-botox-across-multiple-us-states/2462747/The U.S. Food and Drug Administration (FDA) has issued an alert regarding counterfeit botulinum toxin that has been detected in several states. The agency issued a statement on April 16 noting that it is aware of the issue and is working with the Centers for Disease Control (CDC), state
- New Data Show Efficacy of Topical 0.1% Stabilized Bioactive Retinol for Photoaginghttps://practicaldermatology.com/news/analysis-data-shows-efficacy-topical-01-stabilized-bioactive-retinol-photoaging/2462643/A recent integrated analysis published in the Journal of Drugs in Dermatology showed the efficacy and tolerability of topical 0.1% stabilized bioactive retinol in countering the signs of photoaging. "Advances in formulation science have allowed the production of stabilized bioact
- ARCA biopharma and Oruka Therapeutics Announce Merger Agreementhttps://practicaldermatology.com/news/arca-biopharma-and-oruka-therapeutics-announce-merger-agreement/2462611/ARCA biopharma and Oruka Therapeutics, a privately held biotechnology company developing novel biologics designed to set a new standard for the treatm
- Updated Coding Curbs Complex Repair Billing by Mohs Surgeonshttps://practicaldermatology.com/news/updated-coding-curbs-complex-repair-billing-mohs-surgeons/2462489/Complex repairs billed by Mohs surgeons decreased significantly from 2019 to 2021 in the wake of new coding guidelines, according to a national Medicare analysis. Publishing in Dermatologic Surgery, Christian Gronbeck, MD, of the University of Connecticut, Farmington, and colleag
- Ted Danson Partners with Bristol Myers Squibb for Plaque Psoriasis Campaignhttps://practicaldermatology.com/news/ted-danson-partners-with-bristol-myers-squibb-for-plaque-psoriasis-campaign/2462442/Bristol Myers Squibb has partnered with award-winning actor Ted Danson, who lives with plaque psoriasis, for a new campaign called “
- Study Highlights Orofacial Anomalies in Kindler Epidermolysis Bullosahttps://practicaldermatology.com/news/orofacial-anomalies-in-kindler-epidermolysis-bullosa/2462441/A new study in JAMA Dermatology suggests that hypoplastic pitted amelogenesis imperfecta is a feature of Kindler epidermolysis bullosa (KEB). "Kindler epidermolysis bullosa is a genetic skin-blistering disease associated with recessive inherited pathogenic varia
- New Analysis Provides Evidence-based Recommendations for Vitiligo in Pediatric Patientshttps://practicaldermatology.com/news/evidence-based-recommendations-for-treating-vitiligo-in-pediatric-patients-insights-from-comprehensive-review/2462436/A new consensus statement published in JAMA Dermatology provided evidence-based expert recommendations for the treatment of vitiligo in pediatric, adolescent, and young adult patients. The authors undertook a rigorous examination of existing literature and expert consensus, aimi